LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease
LyGenesis, Inc. announced that the FDA has cleared its Investigational New Drug application and a study will be conducted on the safety and efficacy of its first-in-class novel cell therapy for patients with end stage liver disease (ESLD).
December 30, 2020Read More
Juvenescence Partner AgeX Therapeutics Sublicenses Stem Cell Line for Development of Covid-19 Therapy
AgeX Therapeutics announced that ImStem has obtained a non-exclusive, royalty-bearing sublicense from AgeX for development of ImStem’s investigational product candidate IMS001 for development in COVID-19 and ARDS from other causes. Screen reader support enabled.
October 28, 2020Read More
Juvenescence announces a partnership with Evgen Pharma PLC to license its sulforaphane Sulforadex® stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.
September 15, 2020Read More
Relation Therapeutics Receives $1.3M Grant From the Gates Foundation to Identify Covid-19 Therapeutic Candidates
Relation Therapeutics, announces Project RE, which will apply Relation Therapeutics’ and its partners’ technology to the identification of repurposed drug combinations as potential therapeutic candidates for COVID-19.
September 1, 2020Read More
LyGenesis announces four new peer-reviewed publications highlighting its advancing technology for kidney and liver regeneration.
August 27, 2020Read More
AgeX Therapeutics announces a manufacturing, marketing and distribution agreement with Pluristyx, an advanced therapy tools and services company, to expand access to clinical-grade human pluripotent stem cells for therapeutic applications.
June 16, 2020Read More
Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, is pleased to announce the appointment of Dr. Ellen Donnelly to its Senior Leadership Team.
June 11, 2020Read More
AgeX Therapeutics and Sernova collaborate to engineer Universal Locally Immune Protected Cell Therapies
AgeX, a Juvenescence partner, and Sernova collaborate to utilize AgeX’s UniverCyteTM gene technology to generate immune-protected universal therapeutic cells for the treatment of type I diabetes and hemophilia A.
May 29, 2020Read More
AgeX Therapeutics licensee ImStem Biotechnology announces FDA Cleared Investigational New Drug Application
AgeX Therapeutics, a Juvenescence partner, announced that ImStem Biotechnology has received notification from the FDA that it has cleared the investigational New Drug application to evaluate IMS001 for the treatment of multiple sclerosis.
March 20, 2020Read More
AgeX Therapeutics to collaborate with University of California, Irvine on Neural Stem Cell Research Program
AgeX, a Juvenescence partner, announced a research collaboration with the UC Irvine using AgeX’s PureStem® to derive neural stem cells with the goal of developing cellular therapies to treat neurological disorders and diseases with no cure.
February 3, 2020Read More
AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells
AgeX, a Juvenescence partner, announced a research collaboration with a Japanese biopharma company utilizing AgeX’s HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells.
January 29, 2020Read More
Insilico Medicine, a Juvenescence partner, enters into research collaboration with Pfizer Inc. to utilize Insilico’s machine learning technology to identify evidence for potential therapeutic targets implicated in a variety of diseases.
January 14, 2020Read More
NetraMark Corp. and Juvenescence are excited to announce the extension of their collaboration agreement to include drug repurposing and drug discovery.
December 10, 2019Read More
At the end of its first year as a public company, Juvenescence partner AgeX issues a letter shareholders reflecting on progress made, as well as current initiatives and future plans.
December 9, 2019Read More